Rapport Therapeutics price target raised to $56 from $35 at Stifel

Stifel raised the firm’s price target on Rapport Therapeutics (RAPP) to $56 from $35 and keeps a Buy rating on the shares after the company reported topline RAP-219 Phase 2a data in focal onset seizures that the firm says “clearly exceeded expectations.” The effect-size is “so large that we are increasingly confident” in the probability-of-success for the Phase 3 trial, the analyst tells investors.